Echocardiographic measurements in doxorubicin-treated mice
Measurements shown are matched from 6–9 days after injection. Cbr1 +/− mice are different from +/+ mice and equivalent to untreated controls at a statistically significant level for all manifestations (P < 0.002). Mean values ± SE are shown. Cbr1 +/− mice were still equivalent to controls at 15 days after injection (P < 0.004) after most +/+ mice had died. Untreated control data include combined data from both genotypes. LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; IVSD, interventricular septal wall thickness at end diastole; LVPWTD, left ventricular posterior wall thickness at end diastole; FS, fractional shortening; EF, ejection fraction; HR, heart rate.
| Cbr1 +/+ (n = 7) | Cbr1 +/− (n = 8) | Untreated (n = 8) | |
|---|---|---|---|
| LVEDD (mm) | 3.40 ± 0.10 | 2.74 ± 0.08 | 2.96 ± 0.03 |
| LVESD (mm) | 2.06 ± 0.16 | 1.07 ± 0.08 | 1.03 ± 0.01 |
| IVSD (mm) | 0.55 ± 0.07 | 0.76 ± 0.06 | 0.86 ± 0.01 |
| LVPWTD (mm) | 0.51 ± 0.05 | 0.78 ± 0.06 | 0.86 ± 0.01 |
| FS (%) | 39.7 ± 3.8 | 60.6 ± 3.4 | 65.2 ± 0.2 |
| EF (%) | 62.9 ± 4.0 | 83.9 ± 3.2 | 87.9 ± 0.1 |
| HR (beats/min) | 343 ± 61 | 649 ± 16 | 656 ± 3 |